ANI Other Operating Expenses from 2010 to 2024

ANIP Stock  USD 65.43  0.71  1.07%   
ANI Pharmaceuticals Other Operating Expenses yearly trend continues to be relatively stable with very little volatility. Other Operating Expenses is likely to grow to about 459.2 M this year. Other Operating Expenses is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. View All Fundamentals
 
Other Operating Expenses  
First Reported
1999-06-30
Previous Quarter
116.4 M
Current Value
122.9 M
Quarterly Volatility
29.4 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI main balance sheet or income statement drivers, such as Depreciation And Amortization of 62.8 M, Interest Expense of 28.9 M or Selling General Administrative of 157.9 M, as well as many exotic indicators such as Price To Sales Ratio of 1.94, Dividend Yield of 0.0031 or PTB Ratio of 2.18. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement ANI Pharmaceuticals' financial leverage analysis and stock options assessment as well as various ANI Pharmaceuticals Technical models . Check out the analysis of ANI Pharmaceuticals Correlation against competitors.
To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

Latest ANI Pharmaceuticals' Other Operating Expenses Growth Pattern

Below is the plot of the Other Operating Expenses of ANI Pharmaceuticals over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ANI Pharmaceuticals. It is also known as ANI Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. ANI Pharmaceuticals' Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ANI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Other Operating Expenses10 Years Trend
Slightly volatile
   Other Operating Expenses   
       Timeline  

ANI Other Operating Expenses Regression Statistics

Arithmetic Mean166,740,009
Geometric Mean92,240,770
Coefficient Of Variation89.99
Mean Deviation119,545,106
Median147,610,000
Standard Deviation150,050,803
Sample Variance22515.2T
Range456.4M
R-Value0.94
Mean Square Error2606.1T
R-Squared0.89
Slope31,698,034
Total Sum of Squares315213.4T

ANI Other Operating Expenses History

2024459.2 M
2023437.3 M
2022342.1 M
2021244.3 M
2020224 M
2019190.1 M
2018166.2 M

About ANI Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include ANI Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. ANI Pharmaceuticals investors use historical funamental indicators, such as ANI Pharmaceuticals's Other Operating Expenses, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in ANI Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ANI Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ANI Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ANI Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Operating Expenses437.3 M459.2 M
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ANI Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ANI Pharmaceuticals' short interest history, or implied volatility extrapolated from ANI Pharmaceuticals options trading.

Pair Trading with ANI Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ANI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with ANI Stock

  0.9VKTX Viking Therapeutics Potential GrowthPairCorr
  0.94ELEV Elevation Oncology Earnings Call This WeekPairCorr

Moving against ANI Stock

  0.69ZURA Zura Bio Limited Financial Report 10th of May 2024 PairCorr
  0.58GILD Gilead Sciences Earnings Call TodayPairCorr
The ability to find closely correlated positions to ANI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ANI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ANI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ANI Pharmaceuticals to buy it.
The correlation of ANI Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ANI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ANI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ANI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether ANI Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if ANI Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Ani Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Ani Pharmaceuticals Stock:
Check out the analysis of ANI Pharmaceuticals Correlation against competitors.
To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for ANI Stock analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Is ANI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.89)
Earnings Share
0.85
Revenue Per Share
27.044
Quarterly Revenue Growth
0.397
Return On Assets
0.0372
The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.